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ABSTRACT:
Evasion of death receptor ligand-induced apoptosis contributs to cancer development 
and progression. To better understand mechanisms conferring resistance to death 
ligands, we screened an siRNA library to identify sequences that sensitize resistant 
cells to fas activating antibody (CH-11). From this screen, we identified the Sterol-
Regulatory Element-Binding Protein 1 (SREBP1), a transcription factor, which 
regulates genes involved in cholesterol and fatty acid synthesis including fatty acid 
synthase. Inhibition of SREBP1 sensitized PPC-1 and HeLa to the death receptor 
ligands CH-11 and TRAIL. In contrast, DU145 prostate cancer cells that are resistant 
to death ligands despite expressing the receptors on their cell surface remained 
resistant to CH-11 and TRAIL after knockdown of SREBP1.  Consistent with the effects 
on cell viability, the addition of CH-11 activated caspases 3 and 8 in HeLa but not DU145 
cells with silenced SREBP1. We demonstrated that knockdown of SREBP1 produced a 
marked decrease in fatty acid synthase expression. Furthermore, genetic or chemical 
inhibition of fatty acid synthase with shRNA or orlistat, respectively, recapitulated 
the effects of SREBP1 inhibition and sensitized HeLa but not DU145 cells to CH-11 
and TRAIL. Sensitization to death receptor ligands by inhibition of fatty acid synthase 
was associated with activation of caspase 8 prior to caspase 9. Neither silencing of 
SREBP1 or fatty acid synthase changed basal expression of the core death receptor 
components Fas, caspase 8, FADD, caspase 3 or FLIP. Thus, inhibition of SREBP1 or 
its downstream target fatty acid synthase sensitizes resistant cells to death ligands.
INTRODUCTION
Effector caspases can be activated through several 
mechanisms including the death receptor pathway. In this 
pathway, death receptor ligands such as Fas ligand (FasL) 
and TNF-related apoptosis-inducing ligand (TRAIL) 
bind cell surface receptors leading to the dimerization 
and activation of the upstream caspase, caspase-8 
with the aid of the adapter protein, FADD. Activated 
caspase-8 then cleaves and activates caspase-3 with or 
without amplification through the mitochondrial pathway 
of caspase activation [1-3]. Defects in this signaling 
pathway can render cells resistant to death receptor 
ligands and render malignant cells resistant to TRAIL, 
thereby limiting the clinical efficacy of this experimental 
therapeutic agent. 
Previous studies by our group and others have 
demonstrated  that  over-expression  of  the  caspase-8 
inhibitor FLIP overcomes resistance to death receptor 
ligands [4-8] and chemical or genetic inhibition of FLIP 
restores sensitivity to death ligands in some cell lines [8-
12]. In other in vitro models, resistance to death receptor 
ligands has been attributed to over-expression of FAP-1, 
the protein-tyrosine phosphatase which interacts with Fas 
and prevents Fas translocation to the cell surface [13-14]. 
Alternatively, resistance to death ligands has been also 
linked to somatic mutations in caspase 8 [15-17].
To identify additional strategies to overcome 
resistance to death receptor stimuli, we screened an 
siRNA library to identify sequences that sensitize resistant Oncotarget 2011; 2:  186 - 196 187 www.impactjournals.com/oncotarget
cells to CH-11. From this screen, we identified the Sterol-
Regulatory  Element-Binding  Protein1,  SREBP1.  This 
gene encodes a transcription factor that binds to the sterol 
regulatory element-1 (SRE1), thereby regulating multiple 
genes involved in fatty acid and sterol biosynthesis 
including fatty acid synthase and HMGCoA reductase 
[18-19]. Here, we demonstrated that silencing of SREBP1 
restored sensitivity to CH-11 and TRAIL through a 
mechanism at least partly related to inhibition of fatty acid 
synthase  expression.  Thus,  this  study  highlights  novel 
mechanisms to overcome resistance to death receptor 
ligands.
RESULTS 
Identification  of  siRNA  that  sensitize  resistant 
cells to CH-11
To identify genetic targets whose inhibition restores 
sensitivity to death receptor ligands, a cell-based high 
throughput screen was performed using the FasL and 
TRAIL-resistant prostate cancer cell line PPC-1 and the 
commercially available Dharmacon siRNA library of 
6080 SMARTpools. Screens were performed in 96 well 
plates to which siRNA were added at 40nM followed 
6 hours later by the addition of agonistic anti-Fas 
monoclonal antibody (CH-11) (50 ng/mL). Cell viability 
was measured 24 hours after siRNA transfection by MTS 
assay. Each plate included controls of untreated cells, 
cells treated only with CH-11, and cells transfected with 
siRNA control. From this screen, we identified 64 genes 
(1%) that decreased viability at least 3 standard deviation 
away from the mean B score of the entire population of 
tested siRNA. These 64 siRNA were retested in secondary 
assays. Twenty of the 64 hits were reproducible on repeat 
testing and induced cell death in the presence of CH-11. 
These 20 siRNA sequences were retested in the presence 
Figure 1: Genetic silencing of SREBP1 sensitizes resistant cells to CH-11. 
A) PPC-1 cells were transfected with four individual siRNA duplexes targeting SREBP1, the Dharmacon SMARTpool or 
control sequences (final concentration 40nM).  Six hours after transfection, cells were treated with CH-11 (50 ng/mL) or buffer control 
for 18 hours. After incubation, cell growth and viability was measured with the MTS assay. Data represent the mean + SD of a representative 
experiment performed in triplicate (* p<0.05, Student t test).
 B) SREBP1 mRNA expression was measured relative to 18S RNA by real-time RT-PCR.  Data points represent the mean ± 
SD percent of SREBP1/18S expression relative to controls (ΔΔCT normalization) from independent experiments performed in triplicate. (** 
p<0.01, Student t test).
 C) PPC-1 cells were transfected with SREBP1 SMARTpool siRNA or control sequences.  24 hours after transfection, total 
cellular proteins were isolated and analyzed by SDS-PAGE immunoblotting using antibodies against SREBP1 and tubulin.
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and absence of CH-11 to identify FasL sensitizers. Of 
these 20 siRNA sequences, 2 sequences reduced cell 
viability in the presence of CH-11 > 50% compared to 
cells treated with control buffer. The other 18 had lesser 
degrees of sensitization. Of these 2 sequences, one was 
FLIP (65% reduction in viability in the presence of CH-
11) and the other was SREBP1 (57% reduction in viability 
in the presence of CH-11). Previously, we demonstrated 
that chemical or genetic knockdown of FLIP sensitizes 
resistant cells to CH-11 [8], thus, validating the efficacy 
of our siRNA screen. Therefore, we investigated SREBP1 
as a potential FasL sensitizer. 
Silencing  of  SREBP1  sensitizes  resistant  tumor 
cells to death receptor ligands
Having  identified  SREBP1  in  our  siRNA  screen, 
we tested the ability of four individual siRNA duplexes 
targeting SREBP1 to sensitize cells to CH-11. All 4 of 
the  individual  duplexes  as  well  as  the  pooled  siRNA 
sensitized the resistant PPC-1 cells to CH-11 and decreased 
expression of SREBP1 protein and mRNA. In contrast, 
no sensitization to CH-11 or knockdown of SRERP1 was 
observed after transfection of control siRNA. (Figure 1). 
Of  note,  SREBP1  knockdown  did  not  sensitize  PPC-1 
cells to VP-16, a stimulus of the mitochondrial pathway 
of caspase activation (data not shown).
To validate the effects of SREBP1 knockdown on 
death receptor sensitization and determine the effects of 
its knockdown in other cell lines, HeLa cervical cancer 
and DU145 prostate cancer cells were stably infected 
with  shRNA  targeting  SREBP1  or  control  sequences. 
Previously we and others have demonstrated DU145 
and HeLa cells are resistant to death ligands despite 
expressing death receptors on the cell surface [8, 20-21]. 
HeLa but not DU145 cells are sensitized to death ligands 
by knockdown of the caspase-8 inhibitor FLIP [8, 20-
21]. SREBP1 target knockdown in both cell lines was 
confirmed by immunoblotting. Moreover, immunoblotting 
Figure 2: Genetic inhibition of SREBP1 sensitizes cells to CH-11 and TRAIL via caspase activation. 
A) HeLa and DU145 were infected with shRNA targeting SREBP1 or control sequences and stable populations selected; 
i) Total cellular proteins were isolated and analyzed by SDS-PAGE immunoblotting using antibodies against SREBP1 and 
actin. * represents the cleaved form of SREBP1 (68 Kda). 
ii) Cells stably infected with shRNA targeting SREBP1 or control sequences were treated with CH-11 (100 ng/mL for 18 
hours) or TRAIL (100 ng/mL 3 hours).  After incubation, cell growth and viability was measured by the MTS assay.  Data represent the 
mean + SD of a representative experiment performed in triplicate (* p<0.05, Student t test). 
B) The same cells infected as above were treated with CH-11 (100 ng/mL).  At increasing times after incubation, total cellular 
proteins were isolated and analyzed by SDS-PAGE immunoblotting using antibodies against caspase-3, caspase-8.  *  represents cleaved 
caspase 3 (17-22Kda) and cleaved caspase 8 (36/40 Kda).
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demonstrated knockdown of both the precursor and active 
cleaved  forms  of  SREBP1  (Figure  2Ai).  To  evaluate 
the effects of SREBP1 inhibition on CH-11 and TRAIL 
sensitization, HeLa and DU145 cells stably expressing 
SREBP1 shRNA or control sequences were treated with 
CH-11, TRAIL or buffer control. After treatment, cell 
growth and viability was measured by the MTS assay. 
In HeLa but not DU145 cells, knockdown of SREBP1 
sensitized cells to both CH-11 and TRAIL (Figure 2Aii). 
Reductions in cell viability were confirmed by PI staining 
and flow cytometry.
Given the ability of SREBP1 knockdown to sensitize 
cells to death ligands, we examined the effects of target 
knockdown on caspase activation. Consistent with the 
effects on cell viability, we observed cleavage of caspases 
3 and 8 and reductions in the pro-forms of these caspases 
in HeLa cells with silenced SREBP1 treated with CH-
11. In contrast, no changes in cleaved caspases 3 and 8 
or the pro-forms were observed in DU145 cells that were 
resistant to CH-11 sensitization by SREBP1 inhibition. Of 
note, no significant changes in these caspases were noted 
in cells treated with CH-11 alone or with knockdown of 
SREBP1 alone (Figure 2B). 
Genetic  and  chemical  inhibition  of  fatty  acid 
synthase sensitizes resistant cells to death receptor 
ligands
SREBP1 positively regulates the expression of genes 
involved in cholesterol and fatty acid synthesis including 
fatty  acid  synthase  (FASN)  and  HMG  CoA  reductase 
(HMGCR)[22-23]. Therefore, we examined changes in 
FASN and HMG CoA protein expression in HeLa cells 
with stable knockdown of SREBP1. In HeLa cells with 
stable  knockdown  of  SERBP1  we  observed  a  marked 
decrease in FASN expression compared to control cells. 
However, no change in HMGCR expression was detected 
(Figure 3A). 
Therefore,  we  tested  whether  silencing  of  FASN 
could  recapitulate  the  effects  of  SREBP1  knockdown 
and sensitize cells to death receptor ligands. HeLa 
and DU145 cells were infected with shRNA targeting 
FASN or control shRNA and stable populations of cells 
selected.  Knockdown  of  FASN  protein  was  confirmed 
by  immunoblotting  (Figure  3B).  Knockdown  of  FASN 
sensitized HeLa to CH-11 and TRAIL, but DU145 cells 
remained resistant (Figure 3C). As a chemical approach 
to confirm the ability of FASN inhibition to sensitize cells 
to death ligands, HeLa and DU145 cells were treated with 
increasing concentrations of the chemical FASN inhibitor, 
orlistat (S)-2-formylamino-4-methyl-pentanoic acid (S)-
1-[[(2S,  3S)-3-hexyl-4-oxo-2-oxetanyl]  methyl]-dodecyl 
ester [24], with and without CH-11 or TRAIL. Orlistat 
sensitized HeLa cells to CH-11 and TRAIL but had no 
effect on DU145 cells (Figure 4A). We also measured 
caspase activation in HeLa cells treated with orlistat 
Figure 3: Genetic knockdown of FASN sensitizes cells to death ligands
 A) HeLa and DU145 cells were infected with shRNA targeting SREBP1 or control sequences and stable populations 
selected as described in materials and methods   Total cellular proteins were isolated and analyzed by SDS-PAGE 
immunoblotting using antibodies against SREBP1, fatty acid synthase (FASN), 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase (HMGCR) and tubulin.
 B) HeLa and DU145 cells were infected with shRNA targeting FASN or control sequences and stable populations selected.   
Total cellular proteins were isolated and analyzed by SDS-PAGE immunoblotting using antibodies against FASN and actin.
 C) HeLa and DU145 cells infected with FASN or control shRNA as in (B) were treated with CH-11 (100 ng/mL for 18 
hours), TRAIL (100ng/mL for 3 hours), or buffer control.  After incubation, cell growth and viability was measured by the MTS 
assay.  
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and CH-11. Caspase-8 activation was observed within 1 
hour of treating HeLa cells with orlistat and CH-11 and 
activation of caspase-8 preceded activation of caspase-9. 
Of note no significant increase in caspase activation was 
seen in HeLa cells treated with either orlistat or CH-11 
alone (Figure 4B). Thus, chemical inhibition of FASN 
mimics the observations with genetic silencing of FASN 
and SREBP1. 
To understand the mechanism by which inhibition 
of SREBP1 and FASN sensitize cells to death ligands, we 
measured changes in cell surface expression of the Fas in 
HeLa cells with knockdown of SREBP1 or treated with 
orlistat. Inhibition of SREBP1 expression with shRNA 
and inhibition of FASN with orlistat did not significantly 
change the abundance of Fas on the plasma membrane 
by flow cytometry (0.9 + 0.05 fold change in geometric 
mean of Fas expression after 50μM Orlistat and 1.23 + 
0.18 fold change geometric mean after SREBP1 silencing, 
both p>0.05 by Student t test). Likewise, we could not 
detect  changes  in  Fas  localization  after  SREBP1  or 
FASN knockdown by shRNA as examined by confocal 
microscopy (data not shown). We also measured expression 
of FADD, FLIP, caspase-8 and caspase-3 expression in 
HeLa cells with knockdown of SREBP1 or treated with 
orlistat. Again, no differences in expression were detected 
(Figure 5A). Thus, inhibition of SREBP1 and FASN does 
not sensitize cells to death ligands by changing expression 
of core components of the death receptor pathway. 
Inhibition of FASN with orlistat has been associated 
with increased production of ceramide [25]. Therefore, 
we measured changes in ceramide after inhibition of 
FASN  and  SREBP1.  Treatment  of  HeLa  cells  with 
orlistat increased production of membrane ceramide at 
concentrations associated with sensitization to death 
ligands.  However,  genetic  knockdown  of  FASN  or 
SREBP1  did  not  increase  ceramide  production  (Figure 
5B). In addition, the ceramide inhibitors Desipramine 
[26], GW4869 [27] and Fumoisin B1 [28] did not abrogate 
the ability of orlistat to sensitize HeLa cells to CH-11 and 
TRAIL, and supplementation with external ceramide did 
Figure 4: Chemical inhibition of FASN sensitizes to CH-11 and activates caspases
A) HeLa and DU145 cells were treated with increasing concentrations of Orlistat and CH-11 (100 ng/mL) for 18 hours.   
After incubation cell growth and viability was measured by MTS assay.  Data represent the mean + SD of a representative experiment 
performed in triplicate.
 B) HeLa cells were incubated with CH-11 (100 ng/mL final concentration) and/or Orlistat (50 μM final concentration ) 
for 0.5 and 1 hour. After incubation, activation of caspases 8 and 9 were assessed by Flow cytometry as described in materials and methods. 
* p<0.05, Student t test. 
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not sensitize the cells to CH-11 (data not shown). Thus, 
in this model, increased ceramide production does not 
appear sufficient to explain sensitization to death receptor 
ligands after SREBP1 and FASN inhibition.
DISCUSSION
Defects in the death receptor pathway of caspase 
activation can render cells resistant to death ligands and 
thereby limit the clinical efficacy of agents such as TRAIL. 
To better understand mechanisms of resistance to death 
ligands and define strategies to overcome such blocks, 
we conducted an siRNA screen to identify sequences 
that sensitize resistant cells to CH-11. From this screen 
we identified SREBP-1. SREBP1 is a transcription factor 
that, upon cleavage to an active form, regulates genes 
involved in lipid and cholesterol metabolism [22, 29]. 
Consistent with its role in lipid metabolism, transgenic 
mice  over-expressing  active  SREBP-1  developed  fatty 
livers with increased triglycerides and cholesteryl esters 
[30].  In  chromatin  precipitation  experiments,  SREBP1 
interacts with target genes related to lipid and insulin 
metabolism.  These  experiments  also  demonstrated  that 
SREBP1 interacts with the cell cycle regulators CDK2 
and E2F4 [31]. While the functional significance of this 
interaction with cell cycle regulators was unclear, these 
results suggest that SREBP1 may also regulate pathways 
beyond lipid metabolism. 
Over-expression  of  SREBP1  appears  related  to 
the pathogenesis and progression of some malignancies 
[32-35].  For  example,  up  regulation  of  SREBP1  and 
its target genes has been associated with progression 
to androgen independence in prostate cancer [36]. In 
addition, gene expression studies have demonstrated up-
regulation of SREBP1 and its target genes in the putative 
stem cell fraction of prostate cancer [37]. It is not fully 
understood, however, how the dysregulation of lipid and 
cholesterol pathways promotes malignant transformation. 
Nonetheless, these data further support targeting these 
pathways as a therapeutic approach for the treatment of 
malignancy.
 SREBP1 is related to a homologous transcription 
factor SREBP2, but the genes under their control differ. 
For example, SREBP1 mainly regulates genes associated 
with fatty acid synthesis and phospholipid pathways 
while SREBP2 primarily regulates genes associated with 
cholesterol synthesis and uptake [38-39]. Of note, in our 
study, we did not identify SREBP2 as a hit in our siRNA 
screen. 
Previously, we and others have demonstrated that 
over-expression  of  the  endogenous  dominant  negative 
homolog of caspase-8, FLIP (c-Fas-associated death 
domain-like IL-1-converting enzyme-like inhibitory 
protein) is one mechanism by which malignant cells 
become resistant to stimuli of the death receptor pathway 
of caspase activation [40-43]. We also demonstrated that 
Figure 5: Effects of SREBP1 or FASN inhibition on levels of core components of the death receptor pathway of caspase 
activation and ceramide.
A) FADD, Caspase 8, Caspase 3 and Flip were studied in HeLa cells treated with increasing concentrations of Orlistat or 
infected with SREBP1 or Control shRNA. Actin was used as loading control. 
B) Membrane ceramide expression was analized by Flow Cytometry after increasing concentrations of Orlistat for 24 
hours or after FASN, SREBP1 or Control silencing shRNA in HeLa cells. *p<0.05, Student t test. 
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inhibition of FLIP protein or mRNA synthesis is sufficient 
to sensitize some cells to the death receptor ligands CH-
11 and TRAIL [8]. Therefore, we examined the effects 
of down-regulating SREBP1 on the expression of FLIP. 
No change in FLIP expression was detected, indicating 
that  inhibition  of  SREBP1  sensitizes  cells  to  CH-11 
and TRAIL independent of changes in FLIP. Rather, 
sensitization to death ligands appears related, at least in 
part, to reductions in fatty acid synthase expression. In 
support of this contention, SREBP1 reduced expression 
of  FASN  and  genetic  or  chemical  inhibition  of  FASN 
recapitulated the effects of SREBP1 knockdown. 
Fatty acid synthase (FASN) catalyzes the synthesis 
of palmitate from acetyl CoA, malonyl CoA and NADPH 
[44]. In normal tissues, except for cycling endometrium 
and  lactating  breast  tissue,  levels  of  FASN  are  low  to 
undetectable [45-46], as the source of fatty acids is 
primarily the diet [46]. In contrast, malignant cells have 
high levels of FASN [47-50], potentially reflecting the 
higher metabolic demands of these tumors. In some 
malignant cells, chemical or genetic silencing of FASN 
induces cell death in vitro and delays tumor growth in 
vivo [51-52]. Some of these studies report that blocking 
FASN  induces  apoptosis  through  a  mechanism  linked 
to increased ceramide production [25]. Therefore, we 
examined  ceramide  production  in  our  cells  system. 
While we also demonstrated increases in ceramide after 
orlistat treatment, this increase did not appear functionally 
important for sensitization to death ligands. In support of 
this contention, genetic knockout of SREBP1 or FASN 
did not increase levels of ceramide. In addition, inhibitors 
of ceramide production did not protect against orlistat-
mediated sensitization to CH-11. Finally, supplementation 
of the medium with ceramide did not sensitize cells to 
CH-11. This observation is in agreement with a study 
by Knowles et al., who also demonstrated that cell death 
induced by orlistat was associated with activation of 
caspase-8 but independent of ceramide[53]. 
In our study, inhibition of SREBP1 or FASN did 
not sensitize DU145 cells to CH-11 or TRAIL despite the 
presence of the death receptors on the cell surface and 
target knockdown by RNAi. Yet, we demonstrated target 
knockdown in these resistant cells. Therefore, further 
work will be required to understand the basis for resistance 
in  these  lines  how  SREBP1  and  FASN  knockdown 
sensitize other cell lines to death receptor ligands. One 
possibility is that SREBP1 and FASN knockdown alterns 
the organization of the plasma membrane and lipids rafts, 
thus changing the localization of the death receptors 
associated to the membrane [54]. Although we could not 
show changes in Fas localization by confocal microscopy, 
more detailed studies on Fas localization using isolated 
lipid rafts might demonstrate changes in death receptor 
localization.
The findings of this study could have therapeutic 
implications. Potentially, the clinical efficacy of TRAIL 
as a treatment for malignancy could be improved by 
combining  TRAIL  with  SREBP1  or  FASN  inhibitors. 
While  small  molecule  inhibitors  of  SREBP1  are  not 
available, orlistat is an FDA-approved chemical inhibitor 
of FASN and could be combined with TRAIL. However, 
in its current formulation, orlistat is poorly absorbed after 
oral administration [55] therefore an oral formulation with 
improved bioavailability or an intravenous formulation of 
orlistat would be required for the treatment of maligancy. 
Thus, in summary, this work highlights mechanisms of 
resistance to death ligands and strategies to overcome this 
resistance.
MATERIALS AND METHODS
Cell lines. 
PPC-1 and DU145 prostate cancer cell lines and 
HeLa cervical cancer cells were cultured in RPMI 1640 
medium. All cells were supplemented with 10% fetal 
bovine  serum  (FBS)  (Hyclone,  Logan,  UT),  penicillin 
(500 IU/mL), and streptomycin (50 µg/mL). All cells were 
cultured at 37 °C in a humid atmosphere with 5% CO2 .
Reagents 
The monoclonal antibody anti-Fas (CH-11) was 
purchased from MBL International Corporation (Woburn, 
MA) and soluble killer TRAIL was purchased from 
Alexis Biochemicals (San Diego, CA). Orlistat, GW4869, 
Fumonisin B1 and Desipramine hydrochloride were 
purchased from Sigma (St. Lois, MO). C16 ceramide was 
obtained from TRC (North York, ON) and was dissolved 
in isopropanol. 
Viability assays 
The CellTiter96 aqueous nonradioactive MTS assay 
was used to measure cell growth and viability according 
to the manufacturer’s instructions (Promega) and as 
described previously [56]. Propidium iodide (PI) staining 
was performed according to manufacturer’s instructions 
(Biovision, Mountain view, CA).
siRNA screen 
PPC-1 cells were plated in 96-well plates in complete 
RPMI medium 18 hours before the siRNA transfection. 
After adhering to the plates, medium was removed and cells 
were treated with aliquots of the the Human Druggable 
siRNA library (6080 siRNA pools) (Dharmacon, IL) 
(final  concentration  40  nM)  with  lipofectamine  2000 Oncotarget 2011; 2:  186 - 196 193 www.impactjournals.com/oncotarget
(Invitrogen, CA) in medium without FBS or antibiotics. 
After 6 hours of incubation, CH-11 was added (50ng/mL 
final concentration) along with FBS and media. Eighteen 
hours later and 24 hours after siRNA transfection, cell 
viability was measured by the MTS assay. Results were 
normalized and corrected for systematic errors using the B 
score[57]. Compounds with a B score value lower than 3 
times the standard deviation were empirically considered 
hits in the assay. 
Plate handling was performed by a CRS Dimension4 
robotics platform equipped with a Linear Plate Transport 
system (LPT) (Thermo Electron, MA). Plate transfer from 
the LPT to online peripherals was carried out by a CRS 
Flip Mover and Vertical Array Loader (Thermo Electron). 
Liquid handling steps were performed by a Biomek FX 
Laboratory Automation Workstation (Beckman Coulter) 
and  ELx405  Magna  cell  washers  (Biotek,  Vermont). 
Robotics integration was controlled by a Polara integration 
software (Thermo Electron).
SREBP1 siRNA transfection
Cells were transfected with siRNA targeting SREBP1 
as above using the SREBP1 SMARTpool (Dharmacon) 
and individual sets of siRNA (Dharmacon): 
Set 1
sense, 5’-UGACUUCCCUGGCCUAUUUUU-3’, 
antisense, 5’-AAAUAGGCCAGGGAAGU CAUU-3’; 
Set 2
 sense, 5’-ACAUUGAGCUCCUCUCUUGUU-3’, 
antisense, 5’-CAAGAGAGGAGCUCAAUGUUU-3’, 
Set 3
sense, 5’-GCGCACUGCUGUCCA CAAAUU-3’, 
antisense, 5’-UUUGUGGACAGCAGUGCGCUU-3’; 
Set 4
sense, 5’-ACACAGACGUGCUCAUGGAUU-3’, 
antisense, 5’-UCCAUGAGCACGUCU GUGUUU-3’. 
Cells transfected with control siRNA (Control #2, 
Dharmacon) was used during the experiments.
shRNA infection
Construction of hairpin-pLKO.1 vectors (carrying a 
puromycin antibiotic resistance gene) containing shRNA 
sequences and production of short hairpin RNA viruses 
has been described in detail [58]. The shRNA targeting the 
SREBP1,  FASN  and  control  coding  sequences  are  as  follows: 
SREBP1, 5’-GCCATCGACTACATTCGCTTT-3’; FASN, 
5-CATGGAGCGTATCTGTGAGAA-3’ and Control 
5’-TGCCCGACAACCACTACCTGA-3’. Lentiviral 
infections were performed essentially as described [59]. 
Briefly, adherent cells were treated with 0.5 mL of the 
virus, followed by overnight incubation (37 ºC, 5% CO2) 
without removing the virus. The next day, viral media was 
replaced with fresh media containing puromycin (2 µg/
mL) to select a population of resistant cells. 
Quantitative real-time polymerase chain reaction 
First-strand cDNA was synthesized from 1 µg of 
DNase-treated total cellular RNA using random primers 
and  SuperScript  II  reverse  transcriptase  (Invitrogen) 
according to the manufacturer’s protocols. Real-time 
PCR assays were performed in triplicate with 5 ng of 
RNA equivalent cDNA, SYBR Green PCR Master mix 
(Applied Biosystems, Foster City, CA, USA), and 400 
nM of gene-specific primers. Reactions were processed 
and analyzed on an ABI 7900 Sequence Detection System 
(Applied Biosystems). Forward/reverse PCR primer 
pairs  for  human  cDNAs  were  as  follows::  SREBP1, 
forward, 5’-GCAAGGCCATCGACTACATT-3’; 
reverse,  5’-GGTCAGTGTGTCCTCCACCT;  FASN, 
forward, 5’-CTGGCTCAGCACCTCTATCC-3’, reverse, 
5’-CTCCAGGTTGTCCCTGTGAT-3’; and 18S, forward, 
5’-AGGAATTGACGGAAGGGCAC-3’; reverse, 
5’-GGACATCTAAGGGCATCACA -3’. Relative mRNA 
expression was determined using the ΔΔCT method as 
described [60].
Immunoblotting
Total cell lysates were prepared from cells as 
described  previously  [60].  Briefly,  cells  were  washed 
with phosphate-buffered saline pH 7.4, and suspended 
in lysis buffer (10 mmol/L Tris, pH 7.4, 150 mmol/L, 
NaCl,  0.1% Triton  X-100,  0.5%  sodium  deoxycholate, 
and 5 mmol/L EDTA) containing protease inhibitors 
(Complete tablets; Roche, IN). Protein concentrations 
were measured by the Bradford assay [61]. Equal 
amounts of protein were subjected to sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS page) 
followed by transfer to polyvinylidene difluoride (PVDF) 
or nitrocellulose membranes. Membranes were probed 
with rabbit anti–SREBP1 (2A4) (1:1000 [v/v]; Santa Cruz 
Biotechnologies, CA), mouse anti–FASN (1:1000 [v/v]), 
anti-FADD (1:2000 [v/v]), anti-caspase 8 (1:1000 [v/v]) 
(BD Transduction labs, San Jose, CA), rabbit anti-caspase 
3 (Cell Signaling, Danvers, MA) β-actin (1:20000 [v/v]) 
or α-tubulin (1:10000 [v/v]) (Sigma, St. Lois, MO), anti-
FLIP  (NF6)  (1:500  [v/v])  ((Alexis  Biochemicals,  San 
Diego, CA) or anti-HMGCR (clone A9) (1:1000 [v/v]) 
(kindly provided by Dr LZ Penn, Ontario Cancer Institute, 
Toronto, Canada). Secondary antibodies were horseradish 
peroxidase-conjugated  goat  anti  mouse  IgG  (1:10  000 
[v/v]) and anti rabbit (1:5000 [v/v]) (GE Healthcare, 
Chalfont  St  Giles,  United  Kingdom).  Detection  was 
performed by the enhanced chemical luminescence 
method (Pierce, Rockford, IL).Oncotarget 2011; 2:  186 - 196 194 www.impactjournals.com/oncotarget
Fas and ceramide expression
Fas  expression  was  measured  using  mouse  anti-
human Fas FITC and mouse IgG1 FITC (BD and Co., 
Mountain View, CA). Ceramide expression was measured 
with  mouse  anti-human  ceramide  (MID  15B4)  (Alexis 
Biochemicals, San Diego, CA), followed by FITC rat anti-
mouse Ig/M (BD and Co., Mountain View, CA). Cells were 
analyzed with a Becton Dickinson FACSCalibur (BD and 
Co., Mountain View, CA) flow cytometer and analyzed by 
FlowJo analysis software (Tree Star, Ashland, OR). 
Caspase activation assay
Activation of caspases 8 and 9 was detected by 
APO LOGIX carboxyfluorescein caspase detection kits 
(Cell Technology, Mountain View, CA) following the 
manufacturers instructions [62].
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